Study: Kaletra doesn't increase risk of birth defects

08/14/2009 | Medscape (free registration)

Babies born to HIV-positive women who took Kaletra were no more likely to have birth defects than infants born to the general population, according to a U.S. study. Researchers said the prevalence of birth defects was 2.4% among women taking the drug, which contains the protease inhibitors lopinavir and ritonavir. Women who took the drug during their first trimester, however, were more likely to have a preterm birth or low-birth-weight baby.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC